Skip to main content

Table 1 Characteristics of study patients

From: Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin

Age (years), median (range) 60.0 (20.0–80.0)
Sex (male/female) (%) 245 (47.5)/ 271 (52.5)
Body weight (kg), median (range) 58.0 (36.35–107.6)
BMI, median (range) 22.7 (15.8–37.0)
Prior treatment for HCV (no/yes) (%) 359 (69.6)/ 157 (30.4)
Initial dose of PEG-IFN (μg), median (range) 80.0 (40.0–150.0)
Initial dose of ribavirin (mg), median (range) 600 (400–1000)
Pretreatment HCV RNA levels (log10 IU/mL), median (range) 6.1 (5.0–7.7)
Platelet count (×103/μL) 161 (43–352)
Hemoglobin (g/dL) 13.9 (9.7–17.9)
Neutrophil count (/μL) 2489 (578–7480)
Alanine aminotransferase (IU/L) 47 (10–485)
LDL-cholesterol (mg/dL) 99 (25–226)
Total-cholesterol (mg/dL) 171 (29–325)
γ-glutamyl transpeptidase (IU/L) 34.5 (7.0–579)
Alfa fetoprotein (ng/mL) 5.0 (0.8–584)
Fibrosis score (F1/F2/F3/F4) (%) 208(45.9)/139(30.7)/69(15.2)/37(8.2)
Activity score (A1/A2/A3/A4) (%) 258(56.1)/178(38.7)/24(5.2)/0(0)
Genetic polymorphisms of rs8099917 (TT/GG or TG) (%) 288 (72.7)/ 108(27.3)
Amino acid at residue 70 of HCV core (arginine/glutamine or histidine) (%) 242 (67.0)/ 119 (33.0)
Amino acid sequence of ISDR (non-wild-type/wild-type) (%) 110 (26.4)/ 306 (73.6)
  1. BMI, body mass index; HCV, hepatitis C virus; PEG-IFN, peginterferon; ISDR, interferon sensitivity-determining region.
  2. (N = 516).